Sunday, March 17, 2013

IT & ITeS Enterprise in India: an Outsider Perspective based on trends in Investment & Technological Evolution

›
Why should an outsider perspective matter? I tend to believe that way too many people have taken Steve Jobs maxim, ‘ customers cannot tel...
2 comments:
Sunday, March 10, 2013

Modi's WIEF woes & Why I'm pissed!

›
Not sure who’s pissing me off more… The holier-than-the-pope trio of desi professors that merrily went about occupying Philly then ...
Wednesday, March 6, 2013

Will Mylan's acquisition of Agila benefit Accel Partners?

›
Okay, the story goes like this.... Way back in 2007, Accel partners committed to invest & invested over the next three years 1....
1 comment:
Tuesday, March 5, 2013

What could VCs learn from the recent pharma deals involving biotechs with very early-assets?

›
My response on the blog post " Preclinical Biotech Structured Deals: Reflections on 2013′s Solid Start"   by Bruce Booth - post...
Saturday, March 2, 2013

What when the boundaries blur between VC & PE?

›
My response on the highly thought provoking blog post "Venture Capital 2.0"  by Drug Baron (David Grainger) - posted on 01/Mar/2...
1 comment:
Wednesday, February 27, 2013

Dialog on Drug Baron's post "The Primacy of Statistics: In defense of the pivotal Phase 3 Clinical Trial"

›
The Primacy of Statistics: In defense of the pivotal Phase 3 Clinical Trial By Drug Baron (David Grainger) http://www.tcpinnovation...
Wednesday, February 20, 2013

Has the rise of an Indian sun in drug discovery horizon turned out a no-show? OR is it a mere eclipse?

›
Looking up on google to put together my next post, I typed out the text “ Drug discovery prospects India” and the top most hit was that of...
2 comments: